Member Info for LlamaFarmer

Mark Connor

"We could be looking red on the open and then another increase"

Wasn't a bad call was it?

Singer note - they said this week?

26th June 2025 The Initiation Note, titled "Psyching up for success", has been authored by Dr. Karl Keegan, Head of Life Sciences Research at Singers.

The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.

5lut drop over

Jan 2025 - First nasal spray treatment

https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression

They must be looking over their shoulder, SVNS sub lingual treatments are much cheaper to produce and look to work on a lower dosage.

Under NHS they get 8 + 2 years proprietary ownership before any generic competition is allowed to enter the market place.

U.S.A. for the phase 2 FDA programme the patent term is 20 years.

H t t p s : / / t . m e / +8FD4QMxNcORkYmM0

*************+8fd4qmxncorkymm0

Can't load documents onto here but copies on the Telegram Solvonis Research Group.

2021 - Awakn Formed in Canada by Anthony Tennyson, David Nutt etc.

Kare phase 2 test performs stunningly well - 86% abstinence in AUD trial.

June 2024 Phase 3, More - Kare trial set up in U.K. with NHS paying for and running multiple sites, Awakn/SVNS total costs capped at £800k .

More - Kare reports inital results after 4 - 12 weeks with a six month follow up

12 weeks from June = August First quarters results in!

ONE month afterwards

September 2024 https://www.lse.co.uk/rns/GPL/directorate-change-and-grant-of-options-gfv4371ff126icr.html

Dennis Purcell is appointed, this gentleman runs Aisling Capital $15B fund - Awakn is a tiny Canadian listed Pharma - realise that.

6 Months after June 2024 ( the first cohorts full 6 month abstinence reports are in ) these coincidences happen!

11th December 2024 PTSD positive clinical study https://www.lse.co.uk/rns/GPL/initial-results-university-of-nottingham-rzm7vojrstb3342.html

16th December 2024 https://www.lse.co.uk/rns/GPL/proposed-acquisition-of-awakn-life-sciences-corp-xvngazvkmbo14pt.html

14 Jan 2025 https://www.lse.co.uk/rns/GPL/change-of-name-to-solvonis-therapeutics-plc-9p5um8dgqq7dlwh.html

15th May 2025 https://www.lse.co.uk/rns/SVNS/proposed-equity-fundraising-via-abb-spc10j3x9goi17l.html FULLY FUNDED TO RESULTS.

28th May 2025 https://www.lse.co.uk/rns/SVNS/completion-of-the-acquisition-of-awakn-o053y6gv722v0ra.html

Summary

So they realise everything is working and they will need a bigger boat, Dennis Purcell wants in and is given 45m options at 0.10 to join, he also pays his own money and takes more stock in the placing.

They want the listing on the UK main market instead of the Canadian ( Canada has higher tax - that in itself is another clue as to what they think they have here )

They start putting the message out in the U.K about what they have in the pipeline and put the for sale board up for licensing and partnerships - this needs to happen as SVNS is viewed as a new start business in the U.K, the reality is it was formed for this specific purpose in 2021.

Lead author Professor Celia Morgan, of the University of Exeter, said: “Alcoholism can destroy lives, and we urgently need new ways to help people cut down. We found that controlled, low doses of ketamine combined with psychological therapy can help people stay off alcohol for longer than placebo. This is extremely encouraging, as we normally see three out of every four people returning to heavy drinking within six months of quitting alcohol, so this result represents a great improvement.”

Before the trial, participants were drinking every day, consuming 125 units in a week - the equivalent of 50 pints of strong beer. Participants given ketamine and therapy drank over the recommended guidelines on just five days in total over the six month trial period on average. This represents cutting the risk of death from alcohol-related illnesses from one in eight, to one in 80.

Keep turning it over, far away from 0.13p

5.908B shares in issue, 30 or 300 Million here or there doesn't make a difference.

Traders with large followings who only have a volume indicator don't make much difference, the MM's will use that to fill orders.

Phase 3 NHS and Phase 2b with the FDA, Patents, owned I.P. the pharmaceutical industry - that's what we are here for

Re: MM's They'll watch for the positive tweets from 'known' accounts and like clockwork the instant sells.

They'll dip in and out, then get bored and move on it's what they do.

With 5.908B shares in issue they'll be able to do it as and when.

If you look on twitter the full time traders are leaving the party, they won't have enough volume to do much, MM's will take the opportunity.

Tricky,

Once id loaded what I wanted, I was in open ramp mode at 0.13p, kept posting research notes on it - what I got from most was what you would expect - pi55 off you ramping 6it :) :)

Been following this for 18 months, waited for the last placing and loaded in, grateful no one liked it at 0.13, same as they didn't at 0.10.

The only thing holding it back was.

1.Getting Awakn IP into a UK listing

2.Strengthening the board

3.Funding.

2025 is go time, 2026 should see it stratospheric.

Theyll take 15m again, keep switching it on and off, look out for the after hours trades.

They just bought in the last placing.

Hard to buy much without negotiating the trade.

Approaching Zak Mirs breakout number of 0.28 that then runs straight to 0.45

Still a nothing burger for what this Co have to offer us but a nice interim resting place.

If I was a betting man...

I'd think there is newsflow coming that the Company are working on but keeping quiet about.

Someone's derisked their position as needed some funds.

Many others have taken up the slack which spreads the risk and improves the tightness of the register.

Https://www.youtube.com/watch?v=IIOJdMdS56k